- Fuji Pharma obtains rights to commercialize Donesta®, Mithra’s Hormonal Therapy (HT) product candidate based on Estetrol (E4), in Japan and ASEAN
- 20-year agreement to generate low double digit million development, regulatory and commercialization milestones plus long-term supply revenues
- Exclusive License and Supply agreement follows binding term sheet announced in March 2017
Liège, Belgium, 28 June 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, announces that it has signed an exclusive License and Supply Agreement (LSA) with Fuji Pharma, the leader in Women’s Health in Japan, for the commercialization of Donesta® in Japan and ASEAN territories. Donesta® is Mithra’s next generation Hormone Therapy (HT) candidate for which a dose-finding Phase II study is currently ongoing, with top-line results expected late Q1 2018.